Reference pricing programs can steer patients to lower-price, adequate quality providers, but potential savings to health plans and purchasers are actually modest, according to a study from the National Institute for Health Care Reform.
Reference pricing programs can steer patients to lower-price, adequate quality providers, but potential savings to health plans and purchasers are actually modest, according to a study from the National Institute for Health Care Reform (NIHCR).
The study examined the California Public Employees’ Retirement System (CalPERS), which adopted in 2011 reference pricing for inpatient knee and hip replacements. The plan set an upper limit of $30,000 for hospital facility services for these types of procedures and designated certain in-network hospitals that met the reference price.
Patients who chose to use the designated hospitals were only responsible for the health plans usual cost-sharing amounts. Patients choosing other hospitals were responsible for both the usual cost-sharing amount and any amount above the $30,000 reference price.
Applying this narrow reference pricing program to other privately insured populations would only save a few tenths of a percent of total spending, according to the NIHCR report.
“The potential savings from reference pricing are modest for 2 reasons: shoppable services only account for about a third of total spending, and reference pricing only directly affects prices at the high end of the price distribution,” Chapin White, PhD, a former senior researcher at the Center for Studying Health System Change, now at RAND, and lead author of the study with Megan Eguchi, MPH, a senior programmer analyst at Mathematica Policy Research.
However, applying reference pricing to a broader set of “shoppable” inpatient and ambulatory services would yield potential savings of roughly 5% of total spending, according to the report. Shoppable services were defined as those that could be scheduled in advance with multiple providers in a market performing the service and price data available for the different providers.
“When considering reference pricing, employers and health plans need to weigh the potential for savings against increased plan complexity and financial risk to enrollees, along with the analytical and financial resources needed to create and manage the program,” White said in a statement.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More